Pharmacokinetics of once-daily amikacin in healthy foals and therapeutic drug monitoring in hospitalized equine neonates

Journal of Veterinary Internal Medicine

Volumn 18, Issue 5, 2004, Pages 728-733

  Bucki, Erica Paige ^a   Giguère, Steeve ^a   Macpherson, Margo ^a   Davis, Rachel ^a  

^a University of Florida   (United States)

Author keywords

Aminoglycoside; Antimicrobial; Foals; Minimum inhibitory concentration; Sepsis

Indexed keywords

AMIKACIN;

ANIMAL EXPERIMENT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MONITORING; DRUG POTENCY; FEMALE; GRAM NEGATIVE BACTERIUM; HORSE; HOSPITALIZATION; HYPOXEMIA; MALE; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NONHUMAN; PREMATURITY; SEPSIS; STATISTICAL SIGNIFICANCE;

AMIKACIN; ANIMALS; ANIMALS, NEWBORN; ANOXEMIA; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAM-NEGATIVE BACTERIAL INFECTIONS; HALF-LIFE; HORSE DISEASES; HORSES; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS;

ANIMALIA; BACTERIA (MICROORGANISMS); EQUIDAE; EQUUS CABALLUS; NEGIBACTERIA;

EID: 6444243715     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<728:POOAIH>2.0.CO;2     Document Type: Article

References (37)

1. Gayle JM, Cohen ND, Chaffin MK. Factors associated with survival in septicemic foals: 65 cases (1988-1995). J Vet Intern Med 1998;12:140-146.
2. Marsh PS, Palmer JE. Bacterial isolates from blood and their susceptibility patterns in critically ill foals: 543 cases (1991-1998). J Am Vet Med Assoc 2001;218:1608-1610.
3. Wilson WD, Madigan JE. Comparison of bacteriologic culture of blood and necropsy specimens for determining the cause of foal septicemia: 47 cases (1978-1987). J Am Vet Med Assoc 1989;195: 1759-1763.
4. Paradis MR. Update on neonatal septicemia. Vet Clin North Am Equine Pract 1994;10:109-135.
5. Brewer BD. Neonatal infection. In: Koterba AM, Drummond WH, Kosch PC, eds. Equine Clinical Neonatology. Philadelphia, PA: Lea & Febiger; 1990:295-316.
6. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99.
7. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: Application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11:319-326.
8. Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990;162:408-413.
9. Karlowsky JA, Zhanel GG, Davidson RJ, et al. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38:1165-1168.
10. Green SL, Conlon PD. Clinical pharmacokinetics of amikacin in hypoxic premature foals. Equine Vet J 1993;25:276-280.
11. Green S, Conlon PD, Mama K, et al. Effects of hypoxia and azotaemia on the pharmacokinetics of amikacin in neonatal foals. Equine Vet J 1992;24:475-479.
12. Wichtel MG, Breuhaus BA, Aucoin D. Relation between pharmacokinetics of amikacin sulfate and sepsis score in clinically normal and hospitalized neonatal foals. J Am Vet Med Assoc 1992;200:1339-1343.
13. Adland-Davenport P, Brown MP, Robinson JD, et al. Pharmacokinetics of amikacin in critically ill neonatal foals treated for presumed or confirmed sepsis. Equine Vet J 1990;22:18-22.
14. Reiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978;4(Suppl A):85-101.
15. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22-27.
16. Brewer BD, Koterba AM. Development of a scoring system for the early diagnosis of equine neonatal sepsis. Equine Vet J 1988;20: 18-22.
17. Gibaldi M, Perrier D. Pharmacokinetics. New York, NY: Marcel Dekker; 1982:409-417.
18. Jones RN, Gavan TL, Barry AL. Evaluation of the Sensititre microdilution antibiotic susceptibility system against recent clinical isolates: Three-laboratory collaborative study. J Clin Microbiol 1980; 11:426-429.
19. Gavan TL, Jones RN, Barry AL. Evaluation of the Sensititre system for quantitative antimicrobial drug susceptibility testing: A collaborative study. Antimicrob Agents Chemother 1980;17:464-469.
20. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standards. NCCLS document M31-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
21. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 4th ed. NCCLS document M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997.
22. Freeman CD, Nicolau DP, Belliveau PP, et al. Once-daily dosing of aminoglycosides: Review and recommendations for clinical practice. J Antimicrob Chemother 1997;39:677-686.
23. Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: From concept to clinic. Int J Antimicrob Agents 2002;19:341-348.
24. Godber LM, Walker RD, GE Stein, et al. Pharmacokinetics, nephrotoxicosis, and in vitro antibacterial activity associated with single versus multiple (three times) daily gentamicin treatments in horses. Am J Vet Res 1995;56:613-618.
25. Magdesian KG, Wilson WD, Mihalyi J. 2004. Pharmacokinetics of a high dose of amikacin administered at extended intervals to neonatal foals. Am J Vet Res 2004;65:473-479.
26. Lent-Evers NA, Mathot RA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis. Ther Drug Monit 1999;21:63-73.
27. McKenzie HC, Furr MO. Aminoglycoside antibiotics in neonatal foals. Compend Cont Educ Pract Vet 2003;25:457-469.
28. Janknegt R. Aminoglycoside monitoring in the once- or twice-daily era. The Dutch situation considered. Pharm World Sci 1993;15: 151-155.
29. Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet 2001;40:803-814.
30. Prins JM, Koopmans RP, Buller HR, et al. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microbiol Infect Dis 1995;14:531-535.
31. Tange RA, Dreschler WA, Prins JM, et al. Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial. Clin Otolaryngol 1995;20:118-123.
32. Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: A controlled trial. Am J Med 2003;114:194-198.
33. Kotze A, Bartel PR, Sommers DK. Once versus twice daily amikacin in neonates: Prospective study on toxicity. J Paediatr Child Health 1999;35:283-286.
34. Labaune JM, Bleyzac N, Maire P, et al. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Biol Neonate 2001;80:142-147.
35. Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28:753-764.
36. Divers TJ. Spurious elevations in serum creatinine. In: McKinnon AO, Voss JL, eds. Equine Reproduction. Philadelphia, PA: Lea & Febiger; 1993:1039-1040.
37. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986;5:319-324.